CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
|
Series C Convertible Preferred Stock |
Common Stock |
Additional Paid-in Capital |
Treasury Stock |
Subscription Receivable |
Accumulated Deficit |
Accumulated Other Comprehensive Income (Loss) |
Total |
| Balance at the beginning at Dec. 31, 2024 |
$ 15,507,000
|
|
|
|
|
|
|
|
| Balance at the beginning (in shares) at Dec. 31, 2024 |
973,000
|
|
|
|
|
|
|
|
| Increase (Decrease) in Temporary Equity Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion (in shares) |
(131,000)
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
$ (1,754,000)
|
|
|
|
|
|
|
|
| Balance at the end at Jun. 30, 2025 |
$ 13,753,000
|
|
|
|
|
|
|
|
| Balance at the end (in shares) at Jun. 30, 2025 |
842,000
|
|
|
|
|
|
|
|
| Balance at the beginning at Dec. 31, 2024 |
|
$ 1,328,000
|
$ 1,344,720,000
|
|
$ (79,000)
|
$ (1,443,499,000)
|
$ 3,043,000
|
$ (94,487,000)
|
| Balance at the beginning (in shares) at Dec. 31, 2024 |
|
1,328,622,000
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
|
$ 4,000
|
1,750,000
|
|
|
|
|
1,754,000
|
| Series C convertible preferred stock conversion (in shares) |
|
3,263,000
|
|
|
|
|
|
|
| Issuance of common stock for cash, net |
|
$ 56,000
|
12,386,000
|
|
|
|
|
12,442,000
|
| Issuance of common stock for cash, net (in shares) |
|
56,138,000
|
|
|
|
|
|
|
| Warrants exercised for cash |
|
|
23,000
|
|
|
|
|
23,000
|
| Warrants exercised for cash (in shares) |
|
104,000
|
|
|
|
|
|
|
| Issuance of common stock for conversion of debt and accrued interest |
|
$ 71,000
|
18,672,000
|
|
|
|
|
18,743,000
|
| Issuance of common stock for conversion of debt and accrued interest (in shares) |
|
70,484,000
|
|
|
|
|
|
|
| Stock-based compensation |
|
|
749,000
|
|
|
|
|
749,000
|
| Stock-based compensation (in shares) |
|
150,000
|
|
|
|
|
|
|
| Warrant modifications |
|
|
825,000
|
|
|
|
|
825,000
|
| Deemed dividend related to warrant modifications |
|
|
(825,000)
|
|
|
|
|
(825,000)
|
| Net loss |
|
|
|
|
|
(34,721,000)
|
|
(34,721,000)
|
| Cumulative translation adjustment |
|
|
|
|
|
|
(4,892,000)
|
(4,892,000)
|
| Balance at the end at Jun. 30, 2025 |
|
$ 1,459,000
|
1,378,300,000
|
|
(79,000)
|
(1,478,220,000)
|
(1,849,000)
|
(100,389,000)
|
| Balance at the end (in shares) at Jun. 30, 2025 |
|
1,458,761,000
|
|
|
|
|
|
|
| Balance at the beginning at Mar. 31, 2025 |
$ 14,641,000
|
|
|
|
|
|
|
|
| Balance at the beginning (in shares) at Mar. 31, 2025 |
904,000
|
|
|
|
|
|
|
|
| Increase (Decrease) in Temporary Equity Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion (in shares) |
(62,000)
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
$ (888,000)
|
|
|
|
|
|
|
|
| Balance at the end at Jun. 30, 2025 |
$ 13,753,000
|
|
|
|
|
|
|
|
| Balance at the end (in shares) at Jun. 30, 2025 |
842,000
|
|
|
|
|
|
|
|
| Balance at the beginning at Mar. 31, 2025 |
|
$ 1,391,000
|
1,360,652,000
|
|
(79,000)
|
(1,462,842,000)
|
1,399,000
|
(99,479,000)
|
| Balance at the beginning (in shares) at Mar. 31, 2025 |
|
1,391,253,000
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
|
$ 2,000
|
886,000
|
|
|
|
|
888,000
|
| Series C convertible preferred stock conversion (in shares) |
|
1,543,000
|
|
|
|
|
|
|
| Issuance of common stock for cash, net |
|
$ 33,000
|
7,286,000
|
|
|
|
|
7,319,000
|
| Issuance of common stock for cash, net (in shares) |
|
33,391,000
|
|
|
|
|
|
|
| Warrants exercised for cash |
|
|
6,000
|
|
|
|
|
6,000
|
| Warrants exercised for cash (in shares) |
|
28,000
|
|
|
|
|
|
|
| Issuance of common stock for conversion of debt and accrued interest |
|
$ 33,000
|
9,106,000
|
|
|
|
|
9,139,000
|
| Issuance of common stock for conversion of debt and accrued interest (in shares) |
|
32,471,000
|
|
|
|
|
|
|
| Stock-based compensation |
|
|
364,000
|
|
|
|
|
364,000
|
| Stock-based compensation (in shares) |
|
75,000
|
|
|
|
|
|
|
| Warrant modifications |
|
|
560,000
|
|
|
|
|
560,000
|
| Deemed dividend related to warrant modifications |
|
|
(560,000)
|
|
|
|
|
(560,000)
|
| Net loss |
|
|
|
|
|
(15,378,000)
|
|
(15,378,000)
|
| Cumulative translation adjustment |
|
|
|
|
|
|
(3,248,000)
|
(3,248,000)
|
| Balance at the end at Jun. 30, 2025 |
|
$ 1,459,000
|
1,378,300,000
|
|
(79,000)
|
(1,478,220,000)
|
(1,849,000)
|
(100,389,000)
|
| Balance at the end (in shares) at Jun. 30, 2025 |
|
1,458,761,000
|
|
|
|
|
|
|
| Balance at the beginning at Dec. 31, 2025 |
$ 12,710,000
|
|
|
|
|
|
|
|
| Balance at the beginning (in shares) at Dec. 31, 2025 |
784,347
|
|
|
|
|
|
|
|
| Increase (Decrease) in Temporary Equity Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion (in shares) |
(146,000)
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
$ (2,312,000)
|
|
|
|
|
|
|
|
| Balance at the end at Jun. 30, 2026 |
$ 10,398,000
|
|
|
|
|
|
|
|
| Balance at the end (in shares) at Jun. 30, 2026 |
637,614
|
|
|
|
|
|
|
|
| Balance at the beginning at Dec. 31, 2025 |
|
$ 1,567,000
|
1,442,830,000
|
$ (12,000)
|
(79,000)
|
(1,503,661,000)
|
(925,000)
|
$ (60,280,000)
|
| Balance at the beginning (in shares) at Dec. 31, 2025 |
|
1,567,433,000
|
|
|
|
|
|
|
| Balance at the beginning (in shares) at Dec. 31, 2025 |
|
|
|
(12,000,000)
|
|
|
|
12,000,000
|
| Increase (Decrease) in Stockholders' Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
|
$ 4,000
|
2,308,000
|
|
|
|
|
$ 2,312,000
|
| Series C convertible preferred stock conversion (in shares) |
|
3,668,000
|
|
|
|
|
|
|
| Issuance of common stock for cash, net |
|
$ 13,000
|
2,991,000
|
|
|
|
|
3,004,000
|
| Issuance of common stock for cash, net (in shares) |
|
12,926,000
|
|
|
|
|
|
|
| Warrants exercised for cash |
|
|
20,000
|
|
|
|
|
20,000
|
| Warrants exercised for cash (in shares) |
|
79,000
|
|
|
|
|
|
|
| Cashless warrant exercise (in shares) |
|
140,000
|
|
|
|
|
|
|
| Issuance of common stock for conversion of debt and accrued interest |
|
$ 96,000
|
20,664,000
|
|
|
|
|
20,760,000
|
| Issuance of common stock for conversion of debt and accrued interest (in shares) |
|
96,259,000
|
|
|
|
|
|
|
| Issuance of common stock as debt offering cost |
|
$ 1,000
|
149,000
|
|
|
|
|
150,000
|
| Issuance of common stock as debt offering cost (in shares) |
|
833,000
|
|
|
|
|
|
|
| Stock-based compensation |
|
|
469,000
|
|
|
|
|
469,000
|
| Warrant modifications |
|
|
664,000
|
|
|
|
|
664,000
|
| Deemed dividend related to warrant modifications |
|
|
(662,000)
|
|
|
|
|
(662,000)
|
| Net loss |
|
|
|
|
|
(12,290,000)
|
|
(12,290,000)
|
| Cumulative translation adjustment |
|
|
|
|
|
|
679,000
|
679,000
|
| Balance at the end at Jun. 30, 2026 |
|
$ 1,681,000
|
1,469,433,000
|
$ (12,000)
|
(79,000)
|
(1,515,951,000)
|
(246,000)
|
$ (45,174,000)
|
| Balance at the end (in shares) at Jun. 30, 2026 |
|
1,681,338,000
|
|
|
|
|
|
|
| Balance at the end (in shares) at Jun. 30, 2026 |
|
|
|
(12,000,000)
|
|
|
|
12,000,000
|
| Balance at the beginning at Mar. 31, 2026 |
$ 12,484,000
|
|
|
|
|
|
|
|
| Balance at the beginning (in shares) at Mar. 31, 2026 |
767,000
|
|
|
|
|
|
|
|
| Increase (Decrease) in Temporary Equity Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion (in shares) |
129,000
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
$ (2,086,000)
|
|
|
|
|
|
|
|
| Balance at the end at Jun. 30, 2026 |
$ 10,398,000
|
|
|
|
|
|
|
|
| Balance at the end (in shares) at Jun. 30, 2026 |
637,614
|
|
|
|
|
|
|
|
| Balance at the beginning at Mar. 31, 2026 |
|
$ 1,619,000
|
1,455,087,000
|
$ (12,000)
|
(79,000)
|
(1,506,730,000)
|
(429,000)
|
$ (50,544,000)
|
| Balance at the beginning (in shares) at Mar. 31, 2026 |
|
1,618,857,000
|
|
|
|
|
|
|
| Balance at the beginning (in shares) at Mar. 31, 2026 |
|
|
|
(12,000,000)
|
|
|
|
|
| Increase (Decrease) in Stockholders' Deficit |
|
|
|
|
|
|
|
|
| Series C convertible preferred stock conversion |
|
$ 3,000
|
2,083,000
|
|
|
|
|
2,086,000
|
| Series C convertible preferred stock conversion (in shares) |
|
3,228,000
|
|
|
|
|
|
|
| Issuance of common stock for cash, net |
|
$ 1,000
|
103,000
|
|
|
|
|
104,000
|
| Issuance of common stock for cash, net (in shares) |
|
538,000
|
|
|
|
|
|
|
| Warrants exercised for cash |
|
|
14,000
|
|
|
|
|
14,000
|
| Warrants exercised for cash (in shares) |
|
54,000
|
|
|
|
|
|
|
| Issuance of common stock for conversion of debt and accrued interest |
|
$ 57,000
|
11,814,000
|
|
|
|
|
11,871,000
|
| Issuance of common stock for conversion of debt and accrued interest (in shares) |
|
57,828,000
|
|
|
|
|
|
|
| Issuance of common stock as debt offering cost |
|
$ 1,000
|
149,000
|
|
|
|
|
150,000
|
| Issuance of common stock as debt offering cost (in shares) |
|
833,000
|
|
|
|
|
|
|
| Stock-based compensation |
|
|
181,000
|
|
|
|
|
181,000
|
| Warrant modifications |
|
|
334,000
|
|
|
|
|
334,000
|
| Deemed dividend related to warrant modifications |
|
|
(332,000)
|
|
|
|
|
(332,000)
|
| Net loss |
|
|
|
|
|
(9,221,000)
|
|
(9,221,000)
|
| Cumulative translation adjustment |
|
|
|
|
|
|
183,000
|
183,000
|
| Balance at the end at Jun. 30, 2026 |
|
$ 1,681,000
|
$ 1,469,433,000
|
$ (12,000)
|
$ (79,000)
|
$ (1,515,951,000)
|
$ (246,000)
|
$ (45,174,000)
|
| Balance at the end (in shares) at Jun. 30, 2026 |
|
1,681,338,000
|
|
|
|
|
|
|
| Balance at the end (in shares) at Jun. 30, 2026 |
|
|
|
(12,000,000)
|
|
|
|
12,000,000
|